Photodegradation Assessment of Calcipotriol in the Presence of UV Absorbers by UHPLC/MSE
Source abstract
Abstract
Calcipotriol, a synthetic vitamin D3 analogue widely used in psoriasis treatment, requires a detailed stability assessment due to its topical application and potential exposure to UV radiation. As a drug applied directly to the skin, calcipotriol is particularly susceptible to photodegradation, which may affect its therapeutic efficacy and safety profile. The present study focuses on the analysis of calcipotriol photostability. An advanced UHPLC/MSE method was employed for the precise determination of calcipotriol and its degradation products. Particular attention was given to the effects of commonly used organic UV filters—approved for use in cosmetic products in both Europe and the USA (benzophenone-3, dioxybenzone, meradimate, sulisobenzone, homosalate, and avobenzone)—on the stability of calcipotriol. Unexpected degradation of calcipotriol was observed in the presence of sulisobenzone. Importantly, this effect was consistently detected in methanolic solution and in the pharmaceutical formulation containing calcipotriol and betamethasone, which is particularly significant from a practical perspective. This finding underscores the necessity of evaluating photostability under real-life conditions, as cosmetic ingredients, when co-applied with topical drugs on the skin, may substantially influence the stability profile of the pharmaceutical active ingredient. The research resulted in the first-time characterization of four degradation products of calcipotriol. The degradation process was found to primarily affect the E-4-cyclopropyl-4-hydroxy-1-methylbut-2-en-1-yl moiety, causing its isomerization to the Z isomer and the formation of diastereomers with either the R or S configuration. Computational analyses using the OSIRIS Property Explorer indicated that none of the five degradation products exhibit a toxicity effect, whereas molecular docking studies suggested possible binding of two of the five degradation products of calcipotriol with the VDR.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Skin Protection and Aging · Pigment Synthesis and Properties · Indoor Air Quality and Microbial Exposure
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Inorganic Chemistry and Pharmaceutical Analytics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
Funding
Polish Ministry of Education and Science
References (35)
Show source-provided references
1. Rendon, A., and Schäkel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.10.3390/ijms20061475 ↗
2. Gisondi, P., Gracia-Cazaña, T., Kurzen, H., and Galván, J. (2024). Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids. J. Clin. Med., 13.10.3390/jcm13154484 ↗
3. Long-term maintenance treatment of psoriasis: The role of calcipotriol/betamethasone dipropionate aerosol foam in clinical practice10.1080/09546634.2021.1998310 ↗
4. Efficacy and safety of agents containing betamethasone dipropionate and calcipotriol in topical therapy of psoriasis
5. Therapeutic Advancements in the Management of Psoriasis: A Clinical Overview and Update
6. Yan, B.X., Chen, X.Y., Ye, L.R., Chen, J.Q., Zheng, M., and Man, X.Y. (2021). Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction. Front. Med., 8.10.3389/fmed.2021.649408 ↗
7. Psoriasis is More Than Skin Disease10.59783/aire.2024.53 ↗
8. A New Calcipotriol/Betamethasone Formulation with Rapid Onset of Action was Superior to Monotherapy with Betamethasone Dipropionate or Calcipotriol in Psoriasis Vulgaris10.1080/00015550252948194 ↗
9. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy10.1007/s00403-014-1485-3 ↗
10. Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients10.1007/s13555-016-0125-6 ↗
11. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris—A randomized phase II study10.3109/09546634.2015.1083935 ↗
12. Kryczyk-Poprawa, A., Kwiecień, A., and Opoka, W. (2019). Photostability of Topical Agents Applied to the Skin: A Review. Pharmaceutics, 12.10.3390/pharmaceutics12010010 ↗
13. Implications of In-Use Photostability: Proposed Guidance for Photostability Testing and Labeling to Support the Administration of Photosensitive Pharmaceutical Products, Part 2: Topical Drug Product10.1002/jps.24396 ↗
14. Interactions between calcipotriene and ultraviolet light10.1016/S0190-9622(97)70217-2 ↗
15. Simultaneous determination of mometasone furoate and calcipotriol in a binary mixture by validated HPLC and chemometric-assisted UV spectrophotometric methods and identification of degradation products by LC-MS
16. Stability Indicating RP-HPLC Method for Estimation of Impurities of Vitamin D3 Analogue and Corticosteroid Used as Antipsoriatic Drugs. An Attempt to Characterize Pre-Calcipotriene10.4236/ajac.2015.613100 ↗
17. Synthesis and Biological Activity of Diastereomeric and Geometric Analogs of Calcipotriol, PRI-2202 and PRI-2205, Against Human HL-60 Leukemia and MCF-7 Breast Cancer Cells10.3390/cancers5041355 ↗
18. Kutner, A., Chodyński, M., Ryznar, T., Fitak, H., Winiarski, J., Górecki, B., Burzyńska, A., and Szelejewski, W. (2010). Process for Preparation of Pharmaceutically Pure Anhydrous Calcipotriol. (US7700580B2), U.S. Patent.
19. Grodner, B., Żołek, T., and Kutner, A. (2023). Nonaqueous Capillary Electrophoretic Separation of Analogs of (24R)-1,24-Dihydroxyvitamin D3 Derivative as Predicted by Quantum Chemical Calculations. Molecules, 28.10.3390/molecules28135055 ↗
20. SynZeal Research (2025, May 27). Calcipotriol Beta Isomer. Available online: https://www.synzeal.com/en/calcipotriol-beta-isomer.
21. Kryczyk-Poprawa, A., Zupkó, I., Bérdi, P., Żmudzki, P., Piotrowska, J., Pękala, E., Berdys, A., Muszyńska, B., and Opok, W. (2021). Photodegradation of Bexarotene and Its Implication for Cytotoxicity. Pharmaceutics, 13.10.3390/pharmaceutics13081220 ↗
22. Kryczyk-Poprawa, A., Zupkó, I., Bérdi, P., Żmudzki, P., Popiół, J., Muszyńska, B., and Opoka, W. (2020). Photostability Testing of a Third-Generation Retinoid-Tazarotene in the Presence of UV Absorbers. Pharmaceutics, 12.10.3390/pharmaceutics12090899 ↗
23. Photostability of Terbinafine Under UVA Irradiation: The Effect of UV Absorbers10.1111/php.13075 ↗
24. Kryczyk, A., Żmudzki, P., and Hubicka, U. (2017). Determination of bifonazole and identification of its photocatalytic degradation products using UPLC-MS/MS. Biomed. Chromatogr., 31.10.1002/bmc.3955 ↗
25. Nitulescu, G., Lupuliasa, D., Adam-Dima, I., and Nitulescu, G.M. (2023). Ultraviolet Filters for Cosmetic Applications. Cosmetics, 10.10.3390/cosmetics10040101 ↗
26. Jesus, A., Sousa, E., Cruz, M.T., Cidade, H., Lobo, J.M.S., and Almeida, I.F. (2022). UV Filters: Challenges and Prospects. Pharmaceuticals, 15.10.3390/ph15030263 ↗
27. Degradation of Organic UV filters in Chlorinated Seawater Swimming Pools: Transformation Pathways and Bromoform Formation10.1021/acs.est.7b02624 ↗
28. (2024, January 14). ICH-Q2 (R2): Guideline on validation of analytical procedures. Proceedings of the International Conference on Harmonization, Geneva, Switzerland. Available online: https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline.
29. Sander, T. (2025, May 30). Osiris Property Explorer. Available online: https://www.organic-chemistry.org/prog/peo/.
30. Crystal Structures of the Vitamin D Nuclear Receptor Liganded with the Vitamin D Side Chain Analogues Calcipotriol and Seocalcitol, Receptor Agonists of Clinical Importance. Insights into a Structural Basis for the Switching of Calcipotriol to a Receptor Antagonist by Further Side Chain Modification10.1021/jm0310582 ↗
31. (2025, April 13). ICH: Q 1 B: Photostability Testing of New Active Substances and Medicinal Products. Available online: https://www.ema.europa.eu/en/ich-q1b-photostability-testing-new-active-substances-medicinal-products-scientific-guideline.
32. Photochemistry of Benzophenone in Solution: A Tale of Two Different Solvent Environments10.1021/jacs.9b07047 ↗
33. Hydrogen Abstraction Reactions by the Triplet States of Ketones10.1021/ja01093a022 ↗
34. Triplet excited states and radical intermediates formed in electron pulse radiolysis of amino and dimethylamino derivatives of benzophenone10.1021/jp014674n ↗
35. LC separation of calcipotriol from its photodegradation products and protection possibilities using adjuvants10.1016/S0731-7085(01)00390-9 ↗